ALLK Allakos Inc

USD 1.44 0.00 0
Icon

Allakos Inc (ALLK) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.44

0.00 (0.00)%

USD 0.13B

0.47M

USD 4.30(+198.61%)

USD 74.67 (+5085.42%)

Icon

ALLK

Allakos Inc (USD)
COMMON STOCK | NSD
USD 1.44
0.00 0
Take a Tour
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.13B

USD 74.67 (+5085.42%)

USD 1.44

Allakos Inc (ALLK) Stock Forecast

Show ratings and price targets of :
USD 4.30
(+198.61%)

Based on the Allakos Inc stock forecast from 3 analysts, the average analyst target price for Allakos Inc is USD 4.30 over the next 12 months. Allakos Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Allakos Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Allakos Inc’s stock price was USD 1.44. Allakos Inc’s stock price has changed by +20.00% over the past week, +35.85% over the past month and -70.06% over the last year.

No recent analyst target price found for Allakos Inc
No recent average analyst rating found for Allakos Inc

Company Overview Allakos Inc

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a...Read More

https://www.allakos.com

975 Island Drive, Redwood City, CA, United States, 94065

131

December

USD

USA

Adjusted Closing Price for Allakos Inc (ALLK)

Loading...

Unadjusted Closing Price for Allakos Inc (ALLK)

Loading...

Share Trading Volume for Allakos Inc Shares

Loading...

Compare Performance of Allakos Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ALLK

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Allakos Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD109.10B 27.47 20.00

ETFs Containing ALLK

Symbol Name ALLK's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Allakos Inc (ALLK) Stock

Based on ratings from 3 analysts Allakos Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, 1 sell and 1 hold ratings.

Unfortunately we do not have enough data on ALLK's stock to indicate if its a good dividend stock.

Based on targets from 3 analysts, the average taret price for ALLK is USD 4.30 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 1.

Unfortunately we do not have enough data on ALLK's stock to indicate if its overvalued.

The last closing price of ALLK's stock was USD 1.44.

The most recent market capitalization for ALLK is USD 0.13B.

Based on targets from 3 analysts, the average taret price for ALLK is projected at USD 4.30 over the next 12 months. This means that ALLK's stock price may go up by +198.61% over the next 12 months.

We can't find any ETFs which contains Allakos Inc's stock.

As per our most recent records Allakos Inc has 131 Employees.

Allakos Inc's registered address is 975 Island Drive, Redwood City, CA, United States, 94065. You can get more information about it from Allakos Inc's website at https://www.allakos.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...